Suppr超能文献

甲状腺功能亢进症的长期抗甲状腺治疗。

Long-term antithyroid treatment in hyperthyroidism.

作者信息

Slingerland D W, Burrows B A

出版信息

JAMA. 1979 Nov 30;242(22):2408-10.

PMID:90740
Abstract

The major drawback to treatment of hyperthyroidism with antithyroid compounds is the reported low rate of remission. Eighty patients have been given long-term (at least one year; average, 4.4 years; range, one to 14 years) continuous treatment with a remission rate of 76% and an average follow-up of 7.8 years (one to 21 years). The prognostic test of suppressed uptake by the thyroid of less than 20% was about 75% accurate in predicting continuing remission when treatment was stopped. Of those in remission, 14 (23%) were treated for one year, 35 (57%) for one to five years, and 12 (20%) for more than five years. Mild reactions occurred in five (6%), hypothyroidism in two (3%). An antithyroid drug is safe and effective therapy for hyperthyroidism.

摘要

用抗甲状腺化合物治疗甲状腺功能亢进的主要缺点是报告的缓解率较低。80例患者接受了长期(至少一年;平均4.4年;范围为1至14年)持续治疗,缓解率为76%,平均随访7.8年(1至21年)。当停止治疗时,甲状腺摄取抑制低于20%的预后测试在预测持续缓解方面的准确率约为75%。在缓解的患者中,14例(23%)接受了一年治疗,35例(57%)接受了一至五年治疗,12例(20%)接受了五年以上治疗。5例(6%)出现轻度反应,2例(3%)出现甲状腺功能减退。抗甲状腺药物是治疗甲状腺功能亢进的安全有效疗法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验